# BPC-157 TB-500 References: The Primary Research and Regulatory Citations

> BPC-157 TB-500 references: the primary research citations behind the Wolverine blend — tendon, angiogenesis, actin-sequestration, and the Thymosin Beta-4 record — plus the FDA 503A regulatory sources. With DOIs and PubMed links.

Every quantitative claim on this terminal resolves to a numbered entry below — the primary peptide research and the FDA regulatory record.

## How to read this register

These are the primary research citations behind the BPC-157 TB-500 terminal. Entries 1-8 are the peer-reviewed peptide literature for the two constituents; entries 9-10 are the FDA regulatory sources behind the [Wolverine legal status and FDA 503A category](/legal-status) page. The blend itself has no controlled trial, so every research entry describes a single compound — BPC-157 or Thymosin Beta-4 / TB-500 — not the combination. Each carries a DOI or a PubMed link for verification. For the same findings answered question by question, see the [frequently asked questions about the blend](/faq).

## References

[1] Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. https://pubmed.ncbi.nlm.nih.gov/14554208/
[2] Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95:323-333. https://pubmed.ncbi.nlm.nih.gov/27847966/
[3] Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004. https://pubmed.ncbi.nlm.nih.gov/15329672/
[4] Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012. https://pubmed.ncbi.nlm.nih.gov/22074294/
[5] Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012. https://pubmed.ncbi.nlm.nih.gov/22962027/
[6] Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. https://pubmed.ncbi.nlm.nih.gov/40756949/
[7] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. https://pubmed.ncbi.nlm.nih.gov/41966639/
[8] Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. https://pubmed.ncbi.nlm.nih.gov/40789979/
[9] U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (Category 2; BPC-157 and "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" entries effective with the September 29, 2023 update); and Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
[10] U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (agenda lists BPC-157 and TB-500 as bulk drug substances being considered for inclusion on the 503A Bulks List). https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026

---

A verification terminal for the BPC-157 TB-500 blend — each constituent finding scanned against its own study, the combination link flagged UNVERIFIED, and the FDA 503A access record read before anything else; no clinic behind the console and nothing here dispensed.